Veracyte, Inc. Announces Multiple Afirma Grid Studies Will Be Presented At Endo 2025

Published: 2025-07-08 16:50:32 ET VCYT

Published on 07/08/2025 at 16:50

Veracyte, Inc. announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July 12-15 in San Francisco. The findings are derived from Veracyte's whole-transcriptome-based Afirma GRID (Genomic Resource for Intelligent Discovery) database and research tool and provide new insights into the molecular drivers and complexity of thyroid cancer. Veracyte's Afirma Genomic Sequencing Classifier (GSC) was developed with RNA whole-transcriptome-derived sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery.

The Afirma GSC also includes Xpression Atlas, the largest thyroid gene variant and fusion panel available, to help inform treatment decisions for patients whose genomic test or cytopathology results are suspicious for cancer. Veracyte also enables physicians to order DNA testing of the TERT promoter gene, which is performed on the same FNA sample, to help further guide treatment decision-making. Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guidance inclusion for tests, along with new insights to support continued innovation and pipeline development.